ArticleJournal of oncology2018
Homocysteine and Digestive Tract Cancer Risk: A Dose-Response Meta-Analysis.
Article in Journal of oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Hyperhomocysteinemia, a risk factor for various health conditions: an umbrella review of systematic reviews with meta-analysis.Aging clinical and experimental research · 2026Pooled it
- Association of MTHFR rs9651118 and TYMS rs2790 Polymorphisms with Risk of Cancers: A Case-Control Study and Meta-analysis.Biochemical genetics · 2025Pooled it
- Homocysteine levels and cancer risk in hypertensive adults across MTHFR C677T genotypes.Scientific reports · 2026Article
- Supersulfide metabolome of exhaled breath condensate applied as diagnostic biomarkers for esophageal cancer.Cancer science · 2025Article
- Hyperhomocysteinemia and Disease-Is 10 μmol/L a Suitable New Threshold Limit?International journal of molecular sciences · 2024Review
- Homocystein, Vitamin B12 and Folic Acid as Screening Biomarkers in Early Diagnosis and Gastric Cancer Monitoring.Medical sciences (Basel, Switzerland) · 2024Article
- Targeting Oncometabolites in Peritoneal Cancers: Preclinical Insights and Therapeutic Strategies.Metabolites · 2023Review
- Assessment of biochemical factors in blood serum of patients with oral squamous cell carcinoma.Dental research journal · 2023Article
- Metabolic Reprogramming of Colorectal Cancer Cells and the Microenvironment: Implication for Therapy.International journal of molecular sciences · 2021Review
- Cysteine and homocysteine as biomarker of various diseases.Food science & nutrition · 2020Review
- Cys34 Adductomics Links Colorectal Cancer with the Gut Microbiota and Redox Biology.Cancer research · 2019Article
- Association between methylenetetrahydrofolate reductase tagging polymorphisms and susceptibility of hepatocellular carcinoma: a case-control study.Bioscience reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHomocysteine, a key component in one-carbon metabolism, is of great importance in remethylation. Many epidemiologic studies have assessed the association between homocysteine and risk of digestive tract cancer, but the results are inconsistent.
objectiveThe objective of our meta-analysis is to assess the association between homocysteine and digestive tract cancer risk.
methodsComprehensive searches were performed on the PubMed, Embase, Cochrane, and Web of Science databases up to September 25, 2018, to identify relevant studies. Thirteen studies were included in the meta-analysis. Odds ratios (ORs) and their corresponding 95% confidence intervals (95% CIs) were used to estimate the strength of the relationship between homocysteine and the risk of digestive tract cancer.
resultsThe pooled OR of digestive tract cancer risk for patients with the highest categories of blood homocysteine levels versus the lowest categories was 1.27 (95% CI, 1.15, 1.39) with no significant heterogeneity observed (
conclusionGenerally, our results indicated that elevated homocysteine was associated with higher risk of digestive tract cancer. That is, homocysteine concentration may be a potential biomarker for occurrence of digestive tract cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.